- Home
- HRTX vs GDL Comparison
HRTX vs GDL Comparison
Compare HRTX & GDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HRTX | GDL |
|---|---|---|
| Founded | 1983 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.1M | 92.2M |
| IPO Year | 2007 | 2006 |
Fundamental Metrics
Financial Performance| Metric | HRTX | GDL |
|---|---|---|
| Price | $0.33 | $8.36 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $4.50 | N/A |
| AVG Volume (30 Days) | ★ 2.7M | 5.7K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.02% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $154,904,000.00 | N/A |
| Revenue This Year | $15.28 | N/A |
| Revenue Next Year | $20.29 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.36 | N/A |
| 52 Week Low | $0.30 | $8.24 |
| 52 Week High | $1.58 | $8.67 |
Technical Indicators
Market Signals| Indicator | HRTX | GDL |
|---|---|---|
| Relative Strength Index (RSI) | 27.65 | 41.08 |
| Support Level | N/A | $8.35 |
| Resistance Level | $0.46 | $8.53 |
| Average True Range (ATR) | 0.04 | 0.05 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 11.40 | 35.04 |
Price Performance
Historical ComparisonAbout HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
About GDL GDL Fund The of Beneficial Interest
GDL Fund is a diversified closed-end management investment company. Its primary investment objective is to achieve absolute returns in various market conditions without excessive risk of capital. The fund seeks to achieve its objective by investing in merger arbitrage transactions and, to a lesser extent, in corporate reorganizations involving stubs, spin-offs, and liquidations.